Search research articles
Contact Us
Filters
Showing results (361-370 of 456) with videos related to
Page
of 46
Sort By:
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
Lancet (London, England)
|
November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
JAMA Oncology
|
October 16, 2025
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review
César Serrano, Sebastian Bauer, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cancer
|
November 18, 2020
Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
William W Tseng, Francesco Barretta, Lorenzo Conti, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
Page
of 46
Search research articles
Search
Showing results (361-370 of 456) with videos related to
Sort By:
Page
of 46
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
Lancet (London, England)
|
November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
JAMA Oncology
|
October 16, 2025
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review
César Serrano, Sebastian Bauer, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cancer
|
November 18, 2020
Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
William W Tseng, Francesco Barretta, Lorenzo Conti, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
Page
of 46